Julie Cooke Sells 700 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Julie Cooke sold 700 shares of Neurocrine Biosciences stock in a transaction on Monday, February 10th. The shares were sold at an average price of $118.28, for a total value of $82,796.00. Following the completion of the transaction, the insider now owns 18,831 shares of the company’s stock, valued at approximately $2,227,330.68. This trade represents a 3.58 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Julie Cooke also recently made the following trade(s):

• On Friday, January 31st, Julie Cooke sold 1,740 shares of Neurocrine Biosciences stock. The shares were sold at an average price of $152.89, for a total value of $266,028.60.

Neurocrine Biosciences Stock Down 0.3 %

NASDAQ NBIX opened at $116.87 on Friday. Neurocrine Biosciences, Inc. has a 52-week low of $110.95 and a 52-week high of $157.98. The business’s 50-day moving average price is $138.28 and its 200 day moving average price is $130.92. The firm has a market cap of $11.65 billion, a P/E ratio of 35.52 and a beta of 0.33.

Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings results on Thursday, February 6th. The company reported $1.00 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.62 by ($0.62). Neurocrine Biosciences had a return on equity of 13.45% and a net margin of 14.49%. As a group, analysts anticipate that Neurocrine Biosciences, Inc. will post 6.53 earnings per share for the current year.

Hedge Funds Weigh In On Neurocrine Biosciences

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Farringdon Capital Ltd. purchased a new position in shares of Neurocrine Biosciences during the fourth quarter worth about $316,000. Marshall Wace LLP purchased a new stake in Neurocrine Biosciences in the 4th quarter valued at approximately $331,000. Dodge & Cox boosted its holdings in Neurocrine Biosciences by 134.2% in the 4th quarter. Dodge & Cox now owns 3,016,425 shares of the company’s stock valued at $411,742,000 after purchasing an additional 1,728,605 shares in the last quarter. Bridgewater Associates LP boosted its holdings in Neurocrine Biosciences by 146.0% in the 4th quarter. Bridgewater Associates LP now owns 332,598 shares of the company’s stock valued at $45,400,000 after purchasing an additional 197,412 shares in the last quarter. Finally, Aware Super Pty Ltd as trustee of Aware Super purchased a new stake in Neurocrine Biosciences in the 4th quarter valued at approximately $2,139,000. Hedge funds and other institutional investors own 92.59% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have weighed in on NBIX shares. Guggenheim cut their price target on Neurocrine Biosciences from $165.00 to $163.00 and set a “buy” rating on the stock in a research note on Monday. Piper Sandler restated an “overweight” rating and issued a $160.00 price target on shares of Neurocrine Biosciences in a research note on Monday, December 23rd. UBS Group raised their price target on Neurocrine Biosciences from $162.00 to $176.00 and gave the company a “buy” rating in a research note on Thursday, January 30th. Wedbush cut their price target on Neurocrine Biosciences from $157.00 to $147.00 and set an “outperform” rating on the stock in a research note on Friday, February 7th. Finally, HC Wainwright cut their price target on Neurocrine Biosciences from $190.00 to $185.00 and set a “buy” rating on the stock in a research note on Friday, February 7th. Five analysts have rated the stock with a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $166.90.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.